

membrane, said bioprotective membrane positioned more distal to said housing than said glucose determining means and substantially impermeable to macrophages, and iii) an angiogenic layer, said angiogenic layer positioned more distal to said housing than said bioprotective membrane.

2. (amended) The biological fluid measuring device of Claim 11, wherein [said glucose determining means comprises a membrane containing glucose oxidase] said oxidase is glucose oxidase.

REMARKS

Claims 1-20 were at issue in the pending application. Claims 1-20 were rejected. For clarity, the rejections at issue are set forth below.

- (1) The Examiner has corrected, *ex officio*, incomplete citations to "Published Foreign Patent Applications" (filed by the Applicants on September 1, 1998) to indicate the patent office which published said foreign patent applications.
- (2) The Examiner acknowledges the Applicants election to prosecute claims 1-21, without traverse, in the instant case.
- (3) Claims 1-20 are rejected under 35 U.S.C 103 (a) as being unpatentable over U.S. patent 5,741,330 to Brauker *et al.* in view of U.S. patent 5,190,041 to Palti.

1. *Ex Officio* Correction

The Applicants gratefully acknowledge to Examiner's correction to the Form-1449 filed by the Applicants on September 1, 1998.

2. Election

The Applicants confirm the election of claims 1-20, without traverse, during a telephone conversation with Applicants' attorney, Dr. Peter Carroll, on December 3, 1998.

64